Veracyte, Inc.
VCYT· Nasdaq
VCYTVeracyte, Inc.
Source filing unavailable
| Metric | Q4 2013 | Q4 2012 |
|---|---|---|
| Revenue | $6.84M | $4.46M |
| Net Income | -$5.89M | -$4.84M |
| EPS Diluted | -$0.42 | -$7.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Veracyte, Inc. · CIK 1384101 · Engraved from SEC EDGAR
